IMMUNITYBIO, INC. Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest
IMMUNITYBIO, INC. (IBRX) reported Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest of -$12.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest · last filed 2026-08-04
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$12.00K.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$15.00K.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$14.00K.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$21.00K.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2025 was -$74.00K.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2024 was -$81.00K.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2023 was -$656.00K.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2022 was -$753.00K.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.00K 10-Q · filed 2026-08-04 | -$27.00K 10-Q · filed 2026-08-04 | -$41.00K derived: sum of 3 quarters · filed 2026-08-04 | -$62.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$15.00K 10-Q · filed 2026-05-07 | -$29.00K derived: sum of 2 quarters · filed 2026-05-07 | -$50.00K derived: sum of 3 quarters · filed 2026-05-07 | -$69.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$35.00K derived: sum of 2 quarters · filed 2026-02-23 | -$54.00K derived: sum of 3 quarters · filed 2026-08-04 | -$74.00K 10-K · filed 2026-02-23 |
| 2025-09-30 | -$21.00K 10-Q · filed 2025-11-05 | -$40.00K derived: sum of 2 quarters · filed 2026-08-04 | -$60.00K 10-Q · filed 2025-11-05 | -$77.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$19.00K 10-Q · filed 2026-08-04 | -$39.00K 10-Q · filed 2026-08-04 | -$56.00K derived: sum of 3 quarters · filed 2026-08-04 | -$79.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$20.00K 10-Q · filed 2026-05-07 | -$37.00K derived: sum of 2 quarters · filed 2026-05-07 | -$60.00K derived: sum of 3 quarters · filed 2026-05-07 | -$80.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$40.00K derived: sum of 2 quarters · filed 2026-02-23 | -$60.00K derived: sum of 3 quarters · filed 2026-02-23 | -$81.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | -$23.00K 10-Q · filed 2025-11-05 | -$43.00K derived: sum of 2 quarters · filed 2025-11-05 | -$64.00K 10-Q · filed 2025-11-05 | -$86.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$20.00K 10-Q · filed 2025-08-05 | -$41.00K 10-Q · filed 2025-08-05 | -$63.00K derived: sum of 3 quarters · filed 2026-02-23 | -$123.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$21.00K 10-Q · filed 2025-05-12 | -$43.00K derived: sum of 2 quarters · filed 2026-02-23 | -$103.00K derived: sum of 3 quarters · filed 2026-02-23 | -$437.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$82.00K derived: sum of 2 quarters · filed 2026-02-23 | -$416.00K derived: sum of 3 quarters · filed 2026-02-23 | -$656.00K 10-K · filed 2026-02-23 |
| 2023-09-30 | -$60.00K 10-Q · filed 2024-11-12 | -$394.00K derived: sum of 2 quarters · filed 2024-11-12 | -$634.00K 10-Q · filed 2024-11-12 | -$745.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$334.00K 10-Q · filed 2024-08-12 | -$574.00K 10-Q · filed 2024-08-12 | -$685.00K derived: sum of 3 quarters · filed 2025-03-03 | -$908.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$240.00K 10-Q · filed 2024-05-09 | -$351.00K derived: sum of 2 quarters · filed 2025-03-03 | -$574.00K derived: sum of 3 quarters · filed 2025-03-03 | -$821.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$334.00K derived: sum of 2 quarters · filed 2025-03-03 | -$581.00K derived: sum of 3 quarters · filed 2025-03-03 | -$753.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | -$223.00K 10-Q · filed 2023-11-09 | -$470.00K derived: sum of 2 quarters · filed 2023-11-09 | -$642.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$247.00K 10-Q · filed 2023-08-08 | -$419.00K 10-Q · filed 2023-08-08 | ||
| 2021-12-31 | -$3.06M 10-K · filed 2024-03-19 | |||
| 2021-03-31 | -$867.00K 10-Q · filed 2021-05-14 | |||
| 2020-12-31 | -$2.34M 8-K/A · filed 2021-04-22 | |||
| 2020-03-31 | -$389.00K 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | -$2.38M 8-K/A · filed 2021-04-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |